title: Prevention and reversion of nonalcoholic steatohepatitis in OB/OB mice by S-nitroso-N-acetylcysteine treatment.
abstract: OBJECTIVE
  To evaluate the role oral administration of S-nitroso-N-acetylcysteine (SNAC), a NO donor drug, in the prevention and reversion of NASH in two different animal models.
  
  
  METHODS
  NASH was induced in male ob/ob mice by methionine-choline deficient (MCD) and high-fat (H) diets. Two animal groups received or not SNAC orally for four weeks since the beginning of the treatment. Two other groups were submitted to MCD and H diets for 60 days receiving SNAC only from the 31(st) to the 60(th) day.
  
  
  RESULTS
  SNAC administration inhibited the development of NASH in all groups, leading to a marked decrease in macro and microvacuolar steatosis and in hepatic lipid peroxidation in the MCD group. SNAC treatment reversed the development of NASH in animals treated for 60 days with MCD or H diets, which received SNAC only from the 31(st) to the 60(th) day.
  
  
  CONCLUSIONS
  Oral administration of SNAC markedly inhibited and reversed NASH induced by MCD and H diets in ob/ob mice.
authors.affiliation: Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, Brazil. cpm@usp.br
authors.forename: Claudia P M S
authors.initials: CP
authors.lastname: de Oliveira
authors.forename: Vicência M R
authors.initials: VM
authors.lastname: de Lima
authors.forename: Fernanda I
authors.initials: FI
authors.lastname: Simplicio
authors.forename: Francisco G
authors.initials: FG
authors.lastname: Soriano
authors.forename: Evandro S
authors.initials: ES
authors.lastname: de Mello
authors.forename: Heraldo P
authors.initials: HP
authors.lastname: de Souza
authors.forename: Venâncio A F
authors.initials: VA
authors.lastname: Alves
authors.forename: Francisco R M
authors.initials: FR
authors.lastname: Laurindo
authors.forename: Flair J
authors.initials: FJ
authors.lastname: Carrilho
authors.forename: Marcelo G
authors.initials: MG
authors.lastname: de Oliveira
mesh_terms: D000111:Acetylcysteine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D002784:Cholesterol / Q000097:blood; D005234:Fatty Liver / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology / Q000517:prevention & control; D005978:Glutathione / Q000378:metabolism; D006651:Histocytochemistry; D008297:Male; D051379:Mice; D008820:Mice, Obese; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
chemical_list: D020030:Nitric Oxide Donors; D017392:Thiobarbituric Acid Reactive Substances; D014280:Triglycerides; C024940:S-nitroso-N-acetylcysteine; D002784:Cholesterol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005978:Glutathione; D000111:Acetylcysteine